In this episode of our Therapeutic Science and Strategy Podcast, Joel Sandler, Principal, BioConsulting, Cancer Cell Therapy Lead, sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore:

  • How uncovering non-small-cell lung cancer (NSCLC) and spinal muscular atrophy (SMA) genetics led to record-speed options for patients with rare subtypes
  • How the patient advocacy groups enabled translation
  • How the provider infrastructure is evolving to meet the need for genetic precision
  • What pharma brought upon entering and how the lessons shape their and field’s outlook
  • What’s next for rare disease drug development